CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
REVENUE:
Product Development and Licensing Agreements	$ 28	$ 40	$ 103	$ 65
Contracts and Grants	79	5	228	5
Product Royalties	3,006	2,318	7,224	6,761
Total Revenue	3,113	2,363	7,555	6,831
OPERATING EXPENSE:
Research and Development	11,769	8,594	33,650	22,615
Royalty	3,006	2,318	7,224	6,761
General and Administrative	2,835	2,273	7,372	6,849
Amortization of Acquired Intangible Assets	254	656	836	1,622
Total Operating Expense	17,864	13,841	49,082	37,847
Operating Loss	(14,751)	(11,478)	(41,527)	(31,016)
Investment and Other Income, Net	105	144	436	307
Interest Expense	(381)	(438)	(1,225)	(1,358)
Net Loss	(15,027)	(11,772)	(42,316)	(32,067)
Basic and Diluted Net Loss Per Common Share (Note 3) (in dollars per share)	$ (0.25)	$ (0.27)	$ (0.75)	$ (0.85)
Shares Used in Calculating Basic and Diluted Net Loss per Share (Note 3) (in shares)	59,467	44,136	56,090	37,926
COMPREHENSIVE LOSS:
Net Loss	(15,027)	(11,772)	(42,316)	(32,067)
Other Comprehensive (Loss) Income:
Foreign Currency Translation Adjustments	1	(3)	2	(8)
Unrealized Gain (Loss) on Marketable Securities	52	(117)	121	(89)
Comprehensive Loss	$ (14,974)	$ (11,892)	$ (42,193)	$ (32,164)